Breaking News

Recommending spring Covid boosters, weighing in on PBMs, & developing a weight loss drug given more like a 'vaccine'

February 29, 2024
Reporter, Morning Rounds Writer
Good morning. It's Leap Day today, quite a bit different from the last time around. Let's hope.

vaccines

CDC panel recommends spring Covid boosters for people 65 and older

It's time for people age 65 and older to roll up their sleeves again for an additional Covid-19 shot this spring. Yesterday a panel of experts advising the CDC on vaccines recommended the boosters, which gained the approval of CDC Director Mandy Cohen. This is the third year in a row that spring boosters will be offered, a sign of Covid's continued and year-round transmission. Covid hospitalizations are most common among people 65 and older; people 75 and older are most likely to die from the infection. 

Only about 40% of people 65 and older have received the 2023-2024 vaccine, according to CDC data. They're eligible for a booster if their last shot was at least four months ago. Last fall the panel said people who are moderately or severely immunocompromised must wait two months between doses, and additional doses are given after consultation with a health care provider. STAT's Helen Branswell has more on yesterday's vote.


long covid

New study quantifies 'brain fog' after Covid infection, and not just in long CovidAdobeStock_130536573

Adobe

The first time I heard about brain fog in long Covid was the summer of 2020. In those pre-vaccine days, hospitals were overwhelmed, treatments were few, and some patients struggled to breathe. Later, some of them struggled to think. A new study out yesterday in the New England Journal of Medicine assesses brain fog, using cognitive tests to quantify, in the equivalent of IQ points, how Covid infections affect memory and thinking.

People who recovered from their Covid symptoms in four to 12 weeks had the equivalent of an IQ score three points lower than in uninfected people. Among those with long Covid, the drop was six IQ points. For people who required hospital care, the deficit deepened to nine points. The researchers stress that these were group differences in a large study that individuals might not notice. And those numbers may have an upside: They could be endpoints needed to conduct clinical trials of potential treatments. I have more here.


weight loss drugs

What if Wegovy was 'vaccine-like'?

Here's an interesting intersection of a weight-loss drug and something like a vaccine. Current treatments such as  Wegovy and Zepbound need to be taken once a week, pretty much forever. What if they could be shots given once a year, like a vaccine? Novo Nordisk, which makes Wegovy, is looking into that possibility, Chief Scientific Officer Marcus Schindler told STAT's Elaine Chen yesterday. The occasion was the opening of Novo's new biohub in Lexington, Mass., several miles northwest of Boston.

"We have a very early think tank on: What would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?" he said. "Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?" Read more on the idea's early stages.



drug pricing

White House listening session will take up PBMs

File this under wonky stuff that really matters to our personal budgets. In a bid to combat prescription drug costs, the White House will hold a listening session on Monday in search of ways to reform pharmacy benefit managers, people familiar with the plans told STAT's Ed Silverman for his exclusive story. Attendees will include representatives from the federal government (Lina Khan, who heads the Federal Trade Commission) and industry (Mark Cuban of Cost Plus Drug Company). 

Industry people are expected to provide insights into how the largest pharmacy benefit managers determine which medicines are covered by insurers and employers, as well as prices paid at pharmacy counters. Cuban, whose company seeks to avoid the largest middlemen when reaching benefits agreements with employers, told Ed he will "just convey what our experience has been at Cost Plus and, if they ask, [make] suggestions on what we think can make things better." Read more.


public health

U.K. steps up vaccination campaigns as measles outbreak grows

Florida isn't the only place with a measles outbreak. Cases have been rising globally and the U.K. is no exception. Vaccination rates have fallen steadily over the past decade, prompting an ad campaign to increase vaccination. Given the drop, "it's not really a surprise to us that we've seen a resurgence of measles," said Vanessa Saliba, a consultant epidemiologist at the U.K. Health Security Agency. A modeling study released last year estimates that London could see an outbreak of between 40,000 and 160,000 cases. 

Since October, England has seen more than 600 measles cases, UKHSA officials told reporters yesterday. Most cases have been in children under 5 years old, but vulnerable people would also include adults not vaccinated as children and who were never infected thanks to high levels of population immunity. STAT's Andrew Joseph has more on measles as a canary in the coal mine for the return of other vaccine-preventable diseases.


chronic disease

Age isn't the only dividing line for developing arthritis
Screenshot 2024-02-28 at 1.21.35 PM

National Center for Health Statistics / CDC

If you dig into the latest report on arthritis in adults from the National Center for Health Statistics, you'll see age is closely tied to the condition, in which inflammation leads to pain, redness, heat, and swelling in the joints. It's the leading cause of disability in the U.S., affecting 18.9% of adults in 2022, with women at greater risk than men (21.5% vs. 16.1%). The rate is 3.6% up to age 34 but jumps to 53.9% in people age 75 and older.

Family income is another factor. The prevalence of arthritis fell when family income rose. If family income was below the federal poverty level, the arthritis rate was almost 1 in 4, but if family income was four times the poverty level, that rate dropped to about 1 in 6. Two more differences: Asian adults were less likely than adults of other racial and ethnic groups to have arthritis and adults living outside metropolitan areas were most likely to have arthritis.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Changes at Amazon-owned health services cause alarm among patients, employees, Washington Post

  • Q&A: A biotech VC leader shares her next big bets, STAT
  • The Kinsey Institute, the world's top sex research center, faces existential threat from conservative attacks, The Guardian

  • Adam's Take: An inside look at PIPEs, the financing trend that has biotech abuzz, STAT

Thanks for reading! More tomorrow,

P.S.: Let's end on a brighter note than recalling Feb. 29, 2020, shall we? Or maybe just (to me) a quirkier one: This fascinating Nature study tells us how we humans lost our tails. 


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments